[{"orgOrder":0,"company":"Fisabio","sponsor":"Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fisabio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fisabio \/ Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid","highestDevelopmentStatusID":"1","companyTruncated":"Fisabio \/ Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Al-Azhar University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Al-Azhar University","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Al-Azhar University"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"National University Hospital, Singapore \/ Mundipharma","highestDevelopmentStatusID":"8","companyTruncated":"National University Hospital, Singapore \/ Mundipharma"},{"orgOrder":0,"company":"Tropical Infectious Diseases Research and Education Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tropical Infectious Diseases Research and Education Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Tropical Infectious Diseases Research and Education Center \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Tropical Infectious Diseases Research and Education Center \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Halodine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Halodine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Halodine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Halodine \/ Undisclosed"},{"orgOrder":0,"company":"Veloce BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veloce BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Veloce BioPharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Veloce BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Iowa","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Iowa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"University of Iowa \/ 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"University of Iowa \/ 3M Company"},{"orgOrder":0,"company":"University of Iowa","sponsor":"PROFESSIONAL DISPOSABLES INTERNATIONAL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Iowa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Iowa \/ PROFESSIONAL DISPOSABLES INTERNATIONAL","highestDevelopmentStatusID":"11","companyTruncated":"University of Iowa \/ PROFESSIONAL DISPOSABLES INTERNATIONAL"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Swab","sponsorNew":"Brigham and Women's Hospital \/ 3M Company","highestDevelopmentStatusID":"7","companyTruncated":"Brigham and Women's Hospital \/ 3M Company"},{"orgOrder":0,"company":"Advantage Dental Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Dental Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Dental Services \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Dental Services \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamilton Health Sciences \/ McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ McMaster University"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University | Ontario Clinical Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamilton Health Sciences \/ McMaster University | Ontario Clinical Oncology Group","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ McMaster University | Ontario Clinical Oncology Group"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Emery Pharma","sponsor":"Halodine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emery Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Emery Pharma \/ Halodine","highestDevelopmentStatusID":"1","companyTruncated":"Emery Pharma \/ Halodine"},{"orgOrder":0,"company":"Marin L. Schweizer, PhD","sponsor":"University of Pennsylvania | University of Illinois, Chicago | Washington University School of Medicine | Emory Healthcare | Agency for Healthcare Research and Quality | 3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Marin L. Schweizer, PhD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Marin L. Schweizer, PhD \/ University of Pennsylvania | University of Illinois, Chicago | Washington University School of Medicine | Emory Healthcare | Agency for Healthcare Research and Quality | 3M Company","highestDevelopmentStatusID":"11","companyTruncated":"Marin L. Schweizer, PhD \/ University of Pennsylvania | University of Illinois, Chicago | Washington University School of Medicine | Emory Healthcare | Agency for Healthcare Research and Quality | 3M Company"},{"orgOrder":0,"company":"Loreen Herwaldt","sponsor":"Indiana University | University of Utah | Washington University School of Medicine | University of Texas System | Gabrail Cancer Center Research | PDI Healthcare | Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Loreen Herwaldt","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Loreen Herwaldt \/ Indiana University | University of Utah | Washington University School of Medicine | University of Texas System | Gabrail Cancer Center Research | PDI Healthcare | Centers for Disease Control and Prevention","highestDevelopmentStatusID":"11","companyTruncated":"Loreen Herwaldt \/ Indiana University | University of Utah | Washington University School of Medicine | University of Texas System | Gabrail Cancer Center Research | PDI Healthcare | Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ University of Washington"},{"orgOrder":0,"company":"Advantage Silver Dental Arrest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Advantage Silver Dental Arrest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advantage Silver Dental Arrest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advantage Silver Dental Arrest \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Singapore Polytechnic (SP)","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Mundipharma \/ Singapore Polytechnic (SP)","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Singapore Polytechnic (SP)"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Genome Institute of Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Mundipharma \/ Genome Institute of Singapore","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Genome Institute of Singapore"},{"orgOrder":0,"company":"Sundara Reddy","sponsor":"Microdermis Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Sundara Reddy","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sundara Reddy \/ Microdermis Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Sundara Reddy \/ Microdermis Corporation"}]
Find Clinical Drug Pipeline Developments & Deals for Povidone Iodine
Details :
Betadine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Surgical Wound Infection.
Details :
Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prosthesis-Related Infections.
Sponsor :
Indiana University | University of Utah | Washington University School of Medicine | University of Texas System | Gabrail Cancer Center Research | PDI Healthcare | Centers for Disease Control and Prevention
Details :
Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Surgical Wound Infection.
Sponsor :
Indiana University | University of Utah | Washington University School of Medicine | University of Texas System | Gabrail Cancer Center Research | PDI Healthcare | Centers for Disease Control and Prevention
Details :
Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of COVID-19.
Details :
Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prosthesis-Related Infections.
Details :
Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dental Caries.
Details :
Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of COVID-19.
Details :
Povidone Iodine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.
Details :
This collaboration brings together Emery Pharma's years of experience in antimicrobial and antiviral screening and drug development with Halodine's expertise in topical antiviral drug development.
Reset All
